Datapoint: Kadmon Holdings Scores First FDA Approval

The FDA last week approved Kadmon Holdings’ Rezurock for the treatment of chronic graft-versus-host disease, making the drug both Kadmon’s first-ever FDA approved drug, and the first ROCK2 inhibitor in the graft-versus-host market basket. Among the most advantaged therapies for graft-versus-host disease are Johnson & Johnson and AbbVie’s Imbruvica, which holds covered or better status for 73% of all insured lives under the pharmacy benefit, Incyte Corp.’s Jakafi (72%) and Amgen’s Enbrel (70%).

SOURCE: MMIT Analytics, as of 7/19/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 14

Datapoint: Ochsner to Launch MA Org in Louisiana

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 13

Datapoint: Three States to Launch New Exchange Marketplaces

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 12

Datapoint: Centene Takes on Major Medicare Expansion for 2022

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today